Who Wins From Nature’s Genetic Bounty?
Scientists are harvesting genetic data from microorganisms in a North Yorkshire quarry, fueling a global debate over ownership and profit-sharing of natural genetic resources. Researchers from London-based startup Basecamp Research are collecting samples and digitizing genetic codes for sale to AI companies. This practice of trading digital sequencing information (DSI) has become central to biotechnology research and development. The issue will be a focal point at October’s COP16 biodiversity summit in Cali, Colombia, The Guardian reports.
Developing nations, home to much of the world’s biodiversity, are pushing for a global system requiring companies to pay for genetic data use. Past discoveries underscore the potential value: heat-resistant bacteria crucial for COVID-19 testing and marine organisms used in cancer treatments have generated significant profits. Critics accuse companies of “biopiracy” for commercializing genetic information without compensating source countries. Proposed solutions include a global fund for equitable benefit-sharing, though implementation details remain contentious.
Read more of this story at Slashdot.
Scientists are harvesting genetic data from microorganisms in a North Yorkshire quarry, fueling a global debate over ownership and profit-sharing of natural genetic resources. Researchers from London-based startup Basecamp Research are collecting samples and digitizing genetic codes for sale to AI companies. This practice of trading digital sequencing information (DSI) has become central to biotechnology research and development. The issue will be a focal point at October’s COP16 biodiversity summit in Cali, Colombia, The Guardian reports.
Developing nations, home to much of the world’s biodiversity, are pushing for a global system requiring companies to pay for genetic data use. Past discoveries underscore the potential value: heat-resistant bacteria crucial for COVID-19 testing and marine organisms used in cancer treatments have generated significant profits. Critics accuse companies of “biopiracy” for commercializing genetic information without compensating source countries. Proposed solutions include a global fund for equitable benefit-sharing, though implementation details remain contentious.
Read more of this story at Slashdot.